How to buy Adaptive Biotechnologies (ADPT) shares in Australia

Learn how to easily invest in Adaptive Biotechnologies shares.

Adaptive Biotechnologies Corporation
+ $1.35 ( + 3.52%)

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Adaptive Biotechnologies Corporation is a biotechnology business with stocks listed in the US. Adaptive Biotechnologies shares (ADPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$39.75 – an increase of 4.3% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Adaptive Biotechnologies

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Adaptive Biotechnologies. Find the share by name or ticker symbol: ADPT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Adaptive Biotechnologies reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$33.69, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Adaptive Biotechnologies, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Adaptive Biotechnologies. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Adaptive Biotechnologies stock price (NASDAQ:ADPT)

Use our graph to track the performance of ADPT stocks over time.

Adaptive Biotechnologies shares at a glance

Information last updated 2021-09-17.
52-week rangeUS$29.735 - US$71.25
50-day moving average US$35.312
200-day moving average US$38.4321
Target priceUS$56.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) US$-1.244

Where to buy Adaptive Biotechnologies stock

Name Product Standard brokerage for US shares Currency conversion fee Markets
Superhero share trading
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares
Australia’s lowest-cost broker for ASX shares and ETFs.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
eToro (global stocks)
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Invest
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Adaptive Biotechnologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Considering buying Adaptive Biotechnologies shares?

Before you consider Adaptive Biotechnologies, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.

Show me how

Adaptive Biotechnologies price performance over time

Historical closes compared with the last close of $39.75

1 week (2021-09-09) 3.65%
1 month (2021-08-19) 32.41%
3 months (2021-06-18) 0.76%
6 months (2021-03-19) -5.11%
1 year (2020-09-18) -14.24%
2 years (2019-09-19) 1.87%

Adaptive Biotechnologies financials

Revenue TTM US$133.4 million
Gross profit TTM US$-40,220,000
Return on assets TTM -11.41%
Return on equity TTM -28%
Profit margin -128.33%
Book value 4.928
Market capitalisation US$5.6 billion

TTM: trailing 12 months

Shorting Adaptive Biotechnologies shares

There are currently 4.0 million Adaptive Biotechnologies shares held short by investors – that's known as Adaptive Biotechnologies's "short interest". This figure is 8.4% down from 4.4 million last month.

There are a few different ways that this level of interest in shorting Adaptive Biotechnologies shares can be evaluated.

Adaptive Biotechnologies's "short interest ratio" (SIR)

Adaptive Biotechnologies's "short interest ratio" (SIR) is the quantity of Adaptive Biotechnologies shares currently shorted divided by the average quantity of Adaptive Biotechnologies shares traded daily (recently around 568752.98295455). Adaptive Biotechnologies's SIR currently stands at 7.04. In other words for every 100,000 Adaptive Biotechnologies shares traded daily on the market, roughly 7040 shares are currently held short.

However Adaptive Biotechnologies's short interest can also be evaluated against the total number of Adaptive Biotechnologies shares, or, against the total number of tradable Adaptive Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptive Biotechnologies's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Adaptive Biotechnologies shares in existence, roughly 30 shares are currently held short) or 0.043% of the tradable shares (for every 100,000 tradable Adaptive Biotechnologies shares, roughly 43 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Adaptive Biotechnologies.

Find out more about how you can short Adaptive Biotechnologies stock.

Adaptive Biotechnologies share dividends

We're not expecting Adaptive Biotechnologies to pay a dividend over the next 12 months.

Adaptive Biotechnologies share price volatility

Over the last 12 months, Adaptive Biotechnologies's shares have ranged in value from as little as US$29.735 up to US$71.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptive Biotechnologies's is 0.2561. This would suggest that Adaptive Biotechnologies's shares are less volatile than average (for this exchange).

Adaptive Biotechnologies overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site